Cargando…

Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody

The combined therapeutic potential of an immunocytokine designed to deliver IL-12 to the necrotic regions of solid tumors with an anti-PD-L1 antibody that disrupts the immunosuppressive PD-1/PD-L1 axis yielded a combinatorial benefit in multiple murine tumor models. The murine version of the immunoc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fallon, Jonathan K., Vandeveer, Amanda J., Schlom, Jeffrey, Greiner, John W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Priority Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400526/ https://www.ncbi.nlm.nih.gov/pubmed/28423552 http://dx.doi.org/10.18632/oncotarget.16137

Ejemplares similares

Systemic immunotherapy of superficial mouse bladder cancer with Avelumab (MSB0010718C), an anti-PD-L1 immune checkpoint inhibitor
por: Vandeveer, Amanda, et al.
Publicado: (2015)

Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab
por: Fujii, Rika, et al.
Publicado: (2016)

Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody
por: Nagaya, Tadanobu, et al.
Publicado: (2016)

Product review: avelumab, an anti-PD-L1 antibody
por: Collins, Julie M., et al.
Publicado: (2018)

Enhanced immunotherapy by combining a vaccine with a novel murine GITR ligand fusion protein
por: Morillon, Y. Maurice, et al.
Publicado: (2017)

Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody
por: Donahue, Renee N., et al.
Publicado: (2017)

Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma
por: Rajan, Arun, et al.
Publicado: (2019)

Anti-tumor effects of anti-PD-L1 therapy in an orthotopic bladder tumor model
por: Lyon, Amanda, et al.
Publicado: (2014)

Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types
por: Hicks, Kristin C., et al.
Publicado: (2018)

Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity
por: Verdura, Sara, et al.
Publicado: (2020)

Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy
por: Chin, K., et al.
Publicado: (2017)

NHS-IL12, a Tumor-Targeting Immunocytokine
por: Greiner, John W, et al.
Publicado: (2021)

Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy
por: Knudson, Karin M., et al.
Publicado: (2019)

The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex
por: Jochems, Caroline, et al.
Publicado: (2018)

The immunocytokine NHS-IL12 as a potential cancer therapeutic
por: Fallon, Jonathan, et al.
Publicado: (2014)

Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist
por: Knudson, Karin M, et al.
Publicado: (2020)

Synthetic lethality of a cell-penetrating anti-RAD51 antibody in PTEN-deficient melanoma and glioma cells
por: Turchick, Audrey, et al.
Publicado: (2019)

Evaluation of immune cell subsets of cancer patients treated with Avelumab, a fully human IgG1 anti-PD-L1 MAb capable of mediating ADCC of human tumor cells
por: Lepone, Lauren, et al.
Publicado: (2015)

The combination therapy of oncolytic HSV-1 armed with anti-PD-1 antibody and IL-12 enhances anti-tumor efficacy
por: Xie, Xin, et al.
Publicado: (2021)

The BRD4–NUT Fusion Alone Drives Malignant Transformation of NUT Carcinoma
por: Durall, R. Taylor, et al.
Publicado: (2023)

PPT1 inhibition enhances the antitumor activity of anti–PD-1 antibody in melanoma
por: Sharma, Gaurav, et al.
Publicado: (2020)

PPT1 inhibition enhances the antitumor activity of anti–PD-1 antibody in melanoma
por: Sharma, Gaurav, et al.
Publicado: (2022)

RN765C, a low affinity EGFR antibody drug conjugate with potent anti-tumor activity in preclinical solid tumor models
por: Wong, Oi Kwan, et al.
Publicado: (2018)

Case of fulminant type 1 diabetes induced by the anti‐programmed death‐ligand 1 antibody, avelumab
por: Shibayama, Yui, et al.
Publicado: (2019)

Comparison of SARS-CoV-2 RT-PCR on a high-throughput molecular diagnostic platform and the cobas SARS-CoV-2 test for the diagnostic of COVID-19 on various clinical samples
por: Opota, Onya, et al.
Publicado: (2020)

M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine
por: Knudson, Karin M., et al.
Publicado: (2018)

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
por: Dirix, Luc Y., et al.
Publicado: (2017)

Perifosine as a potential novel anti-telomerase therapy
por: Holohan, Brody, et al.
Publicado: (2015)

Temporal changes within the (bladder) tumor microenvironment that accompany the therapeutic effects of the immunocytokine NHS-IL12
por: Morillon, Y. Maurice, et al.
Publicado: (2019)

Anti-tumoral effect of desmethylclomipramine in lung cancer stem cells
por: Bongiorno-Borbone, Lucilla, et al.
Publicado: (2015)

Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents
por: Sestak, Vit, et al.
Publicado: (2015)

Dual Inhibition of KRAS(G12D) and Pan-ERBB Is Synergistic in Pancreatic Ductal Adenocarcinoma
por: Gulay, Kevin Christian Montecillo, et al.
Publicado: (2023)

Investigation of antibody dependent cellular cytotoxicity as a mechanism of action for a novel anti-PD-L1 monoclonal antibody
por: Boyerinas, Benjamin, et al.
Publicado: (2014)

Inhibition of Mdmx (Mdm4) in vivo induces anti-obesity effects
por: Kon, Ning, et al.
Publicado: (2018)

A ketogenic diet supplemented with medium-chain triglycerides enhances the anti-tumor and anti-angiogenic efficacy of chemotherapy on neuroblastoma xenografts in a CD1-nu mouse model
por: Aminzadeh-Gohari, Sepideh, et al.
Publicado: (2017)

Analyses of functions of an anti-PD-L1/TGFβR2 bispecific fusion protein (M7824)
por: Jochems, Caroline, et al.
Publicado: (2017)

How can we interpret SARS-CoV-2 antibody test results?
por: Føns, Sofie, et al.
Publicado: (2021)

Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt’s lymphoma anti-tumor activity
por: Curtis, Nicola J., et al.
Publicado: (2017)

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
por: O’Neil, Bert H., et al.
Publicado: (2017)

T-cell epitope strength in WAP-T mouse mammary carcinomas is an important determinant in PD1/PD-L1 immune checkpoint blockade therapy
por: Bruns, Michael, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_0dj4c54dqm0v42ib1ij988si4j